Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HTR6 | P50406 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.36 |
| ▸ | HTR2B | P41595 | 1/20 | 0.36 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.36 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8435783 | 1.00 | ALDH1A1 (0.38) | ALDH1A1HTR6LMNASIGMAR1HTR2B | |
| SCHEMBL13356 | 1.00 | ALDH1A1 (0.38) | ALDH1A1HTR6LMNASIGMAR1HTR2B | |
| SCHEMBL18379098 | 0.98 | ALDH1A1 (0.39) | ALDH1A1HTR6LMNASIGMAR1HTR2B | |
| SCHEMBL6639099 | 0.98 | ALDH1A1 (0.39) | ALDH1A1HTR6LMNASIGMAR1HTR2B | |
| SCHEMBL18379019 | 0.98 | ALDH1A1 (0.39) | ALDH1A1HTR6LMNASIGMAR1HTR2B | |
| Hydrochloric Acid SCHEMBL27926198 | 0.95 | ALDH1A1 (0.42) | ALDH1A1HTR6LMNASIGMAR1HTR2B | |
| SCHEMBL18878192 | 0.93 | ALDH1A1 (0.39) | ALDH1A1HTR6LMNASIGMAR1HTR2B | |
| SCHEMBL19337146 | 0.93 | ALDH1A1 (0.39) | ALDH1A1HTR6LMNASIGMAR1HTR2B | |
| SCHEMBL13330130 | 0.91 | HTR6 (0.42) | HTR6LMNASIGMAR1 | |
| SCHEMBL21303874 | 0.89 | SIGMAR1 (0.41) | ALDH1A1HTR6LMNASIGMAR1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7256186-B2 | Gamma secretase inhibitors | SCHERING CORPORATION (US) | 2007-08-14 | — | — | US | disclosed |
| US-20050085506-A1 | Novel gamma secretase inhibitors | SCHERING-PLOUGH CORPORATION AND PHARMACOPEIA, INC. | 2005-04-21 | — | — | US | disclosed |
| US-20040171614-A1 | Novel gamma secretase inhibitors | SCHERING-PLOUGH CORPORATION | 2004-09-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040171614-A1 | Novel gamma secretase inhibitors | BACE1, BACE2, APP | ALDH1A1 4012/4885HTR6 3207/4885LMNA 1178/4885 |
| US-20050085506-A1 | Novel gamma secretase inhibitors | BACE1, BACE2, APP | ALDH1A1 2742/4885HTR6 3253/4885LMNA 1578/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.